Heart failure is one of the most serious and fast-growing health problems in the United States and many other countries.
Millions of people live with the condition, and the number continues to rise as populations age and more people survive heart attacks and other heart diseases.
Heart failure not only affects quality of life, but also leads to frequent hospital stays, major medical costs, and a higher risk of death.
Heart failure happens when the heart cannot pump enough blood to meet the body’s needs. Blood carries oxygen and nutrients throughout the body, so when the heart struggles to do its job, many organs can be affected.
People with heart failure often feel tired, weak, or short of breath. They may also develop swelling in the legs, ankles, or abdomen because fluid builds up inside the body.
Many people think heart failure always means the heart has become weak and cannot squeeze properly. This type is known as heart failure with reduced ejection fraction, sometimes called “weak heart” heart failure. In these patients, the heart’s pumping strength is reduced, making it difficult to send enough blood through the body.
But there is another major form of heart failure that is just as common. In this version, the heart can still pump normally, but it becomes stiff and cannot relax properly between beats.
Because the heart cannot fill with enough blood, the body still does not receive the blood flow it needs. Doctors call this condition heart failure with preserved ejection fraction, or HFpEF. Many people also describe it as “stiff heart” heart failure.
HFpEF has become increasingly common, especially among older adults. Conditions such as high blood pressure, diabetes, obesity, and aging can all increase the risk. Even though millions of people live with HFpEF, doctors still have limited treatment options for it compared with “weak heart” heart failure.
A new study from the University of Vermont has now raised concerns about one of the most commonly used medications in heart patients: beta-blockers.
Beta-blockers are widely prescribed medicines that help slow the heart rate, lower blood pressure, and reduce stress on the heart. Doctors often use them to treat high blood pressure, irregular heart rhythms, chest pain, and recovery after heart attacks.
They are also considered life-saving for people with “weak heart” heart failure because they help the damaged heart work more efficiently and reduce the risk of death.
However, scientists have long questioned whether beta-blockers provide the same benefits for people with “stiff heart” heart failure.
To investigate this issue, researchers reviewed information from a major clinical trial called TOPCAT, which included patients with HFpEF. Around 80% of the participants in the study were taking beta-blockers.
The results surprised the researchers. Patients taking beta-blockers were found to be 74% more likely to be hospitalized for heart failure compared with those who were not taking the medications.
The findings suggest that beta-blockers may not only fail to help some HFpEF patients, but could actually worsen their symptoms.
Researchers believe this may happen because the stiff heart already struggles to relax and fill with blood. Beta-blockers may increase pressure inside the heart, making fluid buildup worse. This can lead to more breathing problems and swelling, which are already major symptoms for people with heart failure.
The study highlights an important issue in medicine. Treatments that work very well for one disease may not automatically work for a similar-looking condition. Doctors have strong evidence supporting beta-blockers for “weak heart” heart failure, but much less evidence for their use in HFpEF.
Because there are still very few proven treatments for HFpEF, doctors often prescribe medications based on experience from other types of heart failure. This study suggests that approach may not always be safe or effective.
The researchers say the findings show an urgent need for more research focused specifically on HFpEF. Better understanding of the condition may help scientists develop treatments designed for the unique problems seen in “stiff heart” heart failure instead of relying on therapies developed for other conditions.
For patients and caregivers, the study is also a reminder to discuss medications carefully with healthcare providers. People with HFpEF may benefit from asking whether their treatment plan is supported by strong evidence for their specific condition.
The researchers, led by Dr. Timothy Plante from the University of Vermont, hope their work will encourage larger studies and more personalized treatment approaches for heart failure patients.
The study was published in the medical journal JAMA Network Open. It adds to growing evidence that heart failure is not a single disease, but a group of conditions that may require very different treatments depending on how the heart is affected.
If you care about heart disease, please read studies that herbal supplements could harm your heart rhythm, and how eating eggs can help reduce heart disease risk.
For more health information, please see recent studies that apple juice could benefit your heart health, and results showing yogurt may help lower the death risks in heart disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
